We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+74.07%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.26B
AUM Growth
+$263M
Cap. Flow
+$190M
Cap. Flow %
8.39%
Top 10 Hldgs %
48.54%
Holding
134
New
22
Increased
21
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$52.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$39.4M
3
APGE icon
Apogee Therapeutics
APGE
+$38.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35.4M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$25M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$65.4M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$30.1M
3
WVE icon
Wave Life Sciences
WVE
+$26.3M
4
ARGX icon
argenx
ARGX
+$16.8M
5
BHVN icon
Biohaven
BHVN
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.88%
2 Technology 3.51%
3 Communication Services 1.85%
4 Consumer Discretionary 0.74%
5 Real Estate 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.44B
$400M 17.66%
9,250,005
-2,009,433
-18% -$65.4M
ONC
2
BeOne Medicines Ltd
ONC
$39.4B
$121M 5.33%
653,721
+90,407
+16% +$18.5M
KYMR icon
3
Kymera Therapeutics
KYMR
$8.94B
$119M 5.28%
2,969,733
– –
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$89.9M 3.97%
2,816,258
+649,034
+30% +$19.5M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.92B
$82.3M 3.64%
1,609,652
+300,000
+23% +$16.8M
ARGX icon
6
argenx
ARGX
$54.1B
$70.8M 3.13%
115,045
-28,602
-20% -$16.8M
BCAX
7
Bicara Therapeutics
BCAX
$1.84B
$57M 2.52%
3,272,827
+200,000
+7% +$4.16M
ARWR icon
8
Arrowhead Research
ARWR
$12.4B
$54.6M 2.41%
2,901,681
+442,903
+18% +$9.12M
NAMS icon
9
NewAmsterdam Pharma
NAMS
$3.34B
$53.9M 2.38%
2,095,638
+1,175,074
+128% +$25M
SEPN
10
Septerna Inc
SEPN
$1.75B
$50.4M 2.23%
+2,202,514
New +$52.1M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$50.3M 2.22%
3,004,677
-254,000
-8% -$4.21M
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$49.8M 2.2%
1,377,701
– –
NMRA icon
13
Neumora Therapeutics
NMRA
$302M
$46.6M 2.06%
4,396,100
+1,789,529
+69% +$21.4M
WVE icon
14
Wave Life Sciences
WVE
$1.2B
$46.4M 2.05%
3,750,491
-1,970,681
-34% -$26.3M
ASND icon
15
Ascendis Pharma A/S
ASND
$16.8B
$40.9M 1.81%
297,321
-50,600
-15% -$6.65M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$11.8B
$38.9M 1.72%
+125,942
New +$35.4M
TBLA icon
17
Taboola.com
TBLA
$1.11B
$36.4M 1.61%
9,969,495
– –
APGE icon
18
Apogee Therapeutics
APGE
$10.2B
$33.9M 1.5%
+747,325
New +$38.1M
MRUS
19
DELISTED
Merus
MRUS
$33M 1.46%
784,412
+102,211
+15% +$4.91M
RNAM
20
DELISTED
Avidity Biosciences
RNAM
$32.8M 1.45%
1,127,295
-313,441
-22% -$13.1M
VERA icon
21
Vera Therapeutics
VERA
$2.36B
$32.1M 1.42%
758,465
-79,463
-9% -$3.52M
DYN icon
22
Dyne Therapeutics
DYN
$4.9B
$31.7M 1.4%
1,347,456
+212,792
+19% +$6.29M
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.12B
$29.2M 1.29%
743,769
– –
LXRX icon
24
Lexicon Pharmaceuticals
LXRX
$1.1B
$28.8M 1.27%
38,918,903
– –
BCYC
25
Bicycle Therapeutics
BCYC
$292M
$25.8M 1.14%
+1,839,398
New +$39.4M
1
2 3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q4 2024 Portfolio in Review

As of Q4 2024, Siren LLC held 134 positions worth $2.26B, up 13% from $2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Siren LLC deployed $190M of net new capital in Q4 2024, opening 22 new positions and adding to 21 existing holdings. Its largest new stake was Septerna Inc: 2,202,514 shares worth $50.4M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $65.4M trimmed.

  • Siren LLC's largest Q4 2024 buy was Septerna Inc: 2,202,514 shares worth $50.4M.
  • Siren LLC added most to NewAmsterdam Pharma in Q4 2024, an estimated $25M increase.
  • Siren LLC's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $65.4M.
  • Siren LLC fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $30.1M.
  • Siren LLC's ten largest holdings make up 49% of its $2.26B portfolio in Q4 2024.
  • Siren LLC opened 22 new positions and closed 16 in Q4 2024.
  • Siren LLC's portfolio value rose 13% quarter-over-quarter to $2.26B.

Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.